Hair Loss on Mounjaro: Why It Happens and What You Can Do

If you have noticed more hair in your brush or on the shower floor since starting Mounjaro, you are not alone. Hair loss on Mounjaro is one of the most common concerns patients raise at our 86 Harley Street clinic, and it can feel alarming when it happens to you. The good news is that the shedding is almost always temporary, well understood by doctors, and manageable with the right approach.

In this article, we explain exactly why hair thinning can happen during tirzepatide treatment, what the clinical trial data actually shows about how common it is, and what evidence-based steps you can take to support your hair while you lose weight safely.

Mounjaro itself does not directly damage hair follicles. The hair loss some patients experience is a well-recognised condition called telogen effluvium, triggered by the physical stress of rapid weight loss rather than by tirzepatide as a molecule. In the SURMOUNT-1 clinical trial, around 5 to 6 percent of participants taking tirzepatide reported hair shedding compared with just 1 percent on placebo. The shedding is temporary and typically resolves within 6 to 12 months once your weight stabilises.

Your hair grows in cycles. At any given time, roughly 85 to 90 percent of your hair is in the active growth phase (anagen), while the rest is in a resting phase (telogen) before naturally falling out. When your body undergoes a significant physiological stress, a larger proportion of hair follicles are pushed prematurely into the telogen phase. Two to three months later, those hairs shed together, which is why the thinning often appears several weeks after starting treatment rather than immediately.

Telogen effluvium is not unique to Mounjaro. It has been documented after major surgery, childbirth, severe illness, crash dieting, and any medication that causes substantial weight loss. A 2025 systematic review published in the International Journal of Dermatology confirmed that GLP-1 receptor agonists as a class are associated with telogen effluvium, with the rate correlating most closely with the speed and degree of weight loss rather than the specific drug used.

The SURMOUNT-1 trial, which enrolled over 2,500 adults with obesity, reported alopecia in approximately 5 to 6 percent of participants on the highest tirzepatide doses (10 mg and 15 mg) compared with 1 percent on placebo. Among those who lost more than 20 percent of their body weight, the incidence rose to approximately 5.3 percent, reinforcing the link between rapid weight reduction and shedding.

Women appear to be more affected than men. Data from the tirzepatide trials found that hair loss occurred in approximately 7.1 percent of female participants compared with less than 1 percent of males. This disparity may reflect hormonal shifts during rapid weight loss, particularly changes in oestrogen and androgen balance that influence the hair growth cycle.

It is worth noting that the vast majority of participants in these trials did not experience any hair changes at all. For those who did, the shedding was classified as mild and resolved without treatment discontinuation.

A retrospective cohort study published in 2025 examined hair loss across multiple GLP-1 receptor agonists and found a consistent pattern: the rate of alopecia correlated with total body weight lost, not with which medication was prescribed. Patients losing weight rapidly on semaglutide, liraglutide, or tirzepatide all showed similar rates of telogen effluvium when the degree of weight loss was comparable.

This is an important distinction. It means that Mounjaro is not uniquely harmful to your hair. Any effective weight-loss intervention, whether pharmacological or surgical, carries a similar risk if the weight comes off quickly. Bariatric surgery, for example, is associated with telogen effluvium rates of 30 to 40 percent in the first year. The 5 to 6 percent seen with tirzepatide is modest by comparison.

When you eat significantly less, as many patients do on Mounjaro due to reduced appetite, you may not be getting enough of the micronutrients your hair needs to grow. Iron, zinc, vitamin D, biotin, and B vitamins all play essential roles in the hair follicle cycle. A calorie deficit without attention to nutritional quality can tip the balance toward shedding.

Protein is especially important. Hair is made almost entirely of a protein called keratin, and your body will deprioritise hair growth if protein intake is inadequate. Current evidence suggests that patients on GLP-1 therapy should aim for 1.2 to 1.6 grams of protein per kilogram of body weight daily. If you are finding it difficult to eat enough protein while your appetite is suppressed, our guide on protein intake on Mounjaro covers practical strategies for meeting your targets.

While telogen effluvium cannot always be prevented entirely, there are evidence-based steps you can take to minimise its severity and support regrowth.

Prioritise protein at every meal. Aim for at least 25 to 30 grams of protein per meal. Good sources include eggs, Greek yoghurt, chicken, fish, tofu, and legumes. If your appetite makes full meals difficult, protein shakes or high-protein snacks between meals can help you reach your daily target.

Check your micronutrient levels. Ask your GP or CutKilo doctor to test your iron (ferritin), vitamin D, zinc, and B12 levels. Deficiencies in any of these can worsen hair shedding independently of weight loss. Correcting a low ferritin level, for example, can make a meaningful difference to hair density within a few months.

Avoid crash-dieting on top of treatment. Mounjaro already reduces your appetite significantly. Adding extreme calorie restriction on top of the medication accelerates weight loss beyond what your body can comfortably adapt to. A steady loss of 0.5 to 1 kg per week places less stress on your hair follicles than losing 2 kg or more weekly.

Be gentle with your hair. While this will not change the underlying physiology, avoiding tight hairstyles, excessive heat styling, and harsh chemical treatments reduces mechanical breakage that can make thinning look worse than it is.

Consider a targeted supplement. Some dermatologists recommend a supplement containing biotin, zinc, and iron for patients experiencing telogen effluvium. There is no high-quality evidence that these prevent GLP-1-associated shedding specifically, but correcting borderline deficiencies is reasonable. Always check with your doctor before starting a new supplement, particularly if you take other medications.

Most hair shedding on Mounjaro is mild and self-limiting. However, you should speak to your CutKilo doctor or GP if the shedding is severe enough to cause visible bald patches, if it continues for more than 6 months without improvement, if you notice other symptoms such as fatigue, brittle nails, or unusual bruising (which may point to a nutritional deficiency), or if you had thinning hair before starting treatment.

In rare cases, your doctor may recommend slowing the dose escalation to reduce the rate of weight loss and give your body more time to adjust. At CutKilo, we tailor every patient’s treatment plan individually, and we can adjust your dose schedule if hair loss is a significant concern for you.

Yes. Current evidence does not support permanent hair follicle damage from tirzepatide or any other GLP-1 receptor agonist. The systematic reviews published to date consistently describe the shedding as temporary, with regrowth typically beginning within 3 to 6 months once your weight stabilises and nutritional status improves.

A scoping review published in Cureus in 2025 examined all available case reports and trial data and concluded that GLP-1-associated alopecia is self-resolving in the overwhelming majority of cases. The review noted that no patients required treatment discontinuation solely for hair loss, and that regrowth was documented in every case where follow-up data was available.

Hair loss on Mounjaro affects a minority of patients and is driven by the body’s response to rapid weight loss rather than by the medication itself. The clinical trial data shows that around 5 to 6 percent of people experience some degree of shedding, with women more commonly affected than men. The condition is called telogen effluvium, it is temporary, and it resolves once weight loss stabilises. Adequate protein, correcting any micronutrient deficiencies, and avoiding excessively rapid weight loss are the most effective strategies to minimise its impact. If you are concerned about hair changes during your treatment, your CutKilo doctor can review your plan and make adjustments to support you.

Does Mounjaro directly cause hair loss? No. Mounjaro does not damage hair follicles directly. The shedding is a form of telogen effluvium caused by the physiological stress of rapid weight loss, not by tirzepatide itself. The same pattern is seen with bariatric surgery and other effective weight-loss treatments.

How long does hair loss on Mounjaro last? Most patients notice shedding beginning 2 to 3 months after starting treatment. It typically lasts for several months and resolves within 6 to 12 months once your weight stabilises. Regrowth usually begins within 3 to 6 months of stabilisation.

Can I prevent hair loss while taking Mounjaro? You can reduce the risk by eating enough protein (1.2 to 1.6 g per kg of body weight daily), maintaining adequate iron, zinc, vitamin D, and B vitamin levels, and avoiding crash dieting on top of your medication. A steady rate of weight loss places less stress on your hair follicles.

Should I stop taking Mounjaro if my hair is falling out? In most cases, no. The hair loss is temporary and does not indicate a serious medical problem. Stopping treatment would interrupt your weight-loss progress without necessarily speeding up hair regrowth. Speak to your CutKilo doctor, who can adjust your dose schedule if the shedding is significant.

Is hair loss more common at higher Mounjaro doses? The SURMOUNT-1 trial data suggests a slightly higher incidence at the 10 mg and 15 mg doses compared with 5 mg, which correlates with greater weight loss at higher doses rather than a direct dose-dependent drug effect on hair.